Author ORCID Identifier
This is an article about how the use of medications such as nirmatrelvir/ritonavir can cause rebound COVID-19 and how the use of Rituximab, a biologic agent, can prolong the duration and increase severity of symptoms of COVID-19 in patients with pre-disposed autoimmune diseases that are on chronic pharmacotherapy.
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Baig RA, Chowdhury F, Siddiqui O, Sheikh A, Mehta V, Dakwale P. Severe COVID-19 following Rituximab and Nirmatrelvir/ritonavir treatment in a patient with MCTD, Case Report. Advances in Clinical Medical Research and Healthcare Delivery. 2023; 3(3). doi: 10.53785/2769-2779.1154.